Shotgun lipidomics for candidate biomarkers of urinary phospholipids in prostate cancer
- 1k Downloads
Qualitative and quantitative profiling of six different categories of urinary phospholipids (PLs) from patients with prostate cancer was performed to develop an analytical method for the discovery of candidate biomarkers by shotgun lipidomics method. Using nanoflow liquid chromatography–electrospray ionization–tandem mass spectrometry, we identified the molecular structures of a total of 70 PL molecules (21 phosphatidylcholines (PCs), 11 phosphatidylethanolamines (PEs), 17 phosphatidylserines (PSs), 11 phosphatidylinositols (PIs), seven phosphatidic acids, and three phosphatidylglycerols) from urine samples of healthy controls and prostate cancer patients by data-dependent collision-induced dissociation. Identified molecules were quantitatively examined by comparing the MS peak areas. From statistical analyses, one PC, one PE, six PSs, and two PIs among the PL species showed significant differences between controls and cancer patients (p < 0.05, Student’s t test), with concentration changes of more than threefold. Cluster analysis of both control and patient groups showed that 18:0/18:1-PS and 16:0/22:6-PS were 99% similar in upregulation and that the two PSs (18:1/18:0, 18:0/20:5) with two PIs (18:0/18:1 and 16:1/20:2) showed similar (>95%) downregulation. The total amount of each PL group was compared among prostate cancer patients according to the Gleason scale as larger or smaller than 6. It proposes that the current study can be utilized to sort out possible diagnostic biomarkers of prostate cancer.
KeywordsPhospholipids Quantitative analysis nLC–ESI–MS/MS Urine Prostate cancer Biomarker
This study was supported by grant NRF-2008-2003136 and in part by grant NRF-2010-0014046 from the National Research Foundation of Korea.
- 3.Hsing AW, Devesa SS (2001) Epidemiol Rev 23:3–13Google Scholar
- 5.Matsuda Y, Miyashita A, Fujimoto Y, Umeda T, Akihama S (1996) Biol Pharm Bull 19:1083–1085Google Scholar
- 7.Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM (2009) Nature 457:910–914CrossRefGoogle Scholar
- 9.Brouwers JFHM, Vernooji EAAM, Tielens AGM, van Golde LMG (1999) J Lipid Res 40:164–169Google Scholar
- 12.Williams CM, Maunder K (1993) Eur J Clin Nutr 47:260–267Google Scholar
- 15.Sutphen R, Xu Y, Wilbanks GD, Fiorica J, Grendys EC Jr, LaPolla JP, Arango H, Hoffman MS, Martino M, Wakeley K, Griffin D, Blanco RW, Cantor AB, Xiao YJ, Krischer JP (2004) Cancer Epidemiol Biomark Prev 13:1185–1191Google Scholar
- 17.Koivusalo M, Haimi P, Heikinheimo L, Kostiainen R, Somerharju P (2001) J Lipid Res 42:663–672Google Scholar